HomeCompareSAGE vs PLD

SAGE vs PLD: Dividend Comparison 2026

SAGE yields 23.04% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.82M in total portfolio value· pulled ahead in Year 6
10 years
SAGE
SAGE
● Live price
23.04%
Share price
$8.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$87.8K
Annual income
$9,210.28
Full SAGE calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SAGE vs PLD

📍 PLD pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAGEPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAGE + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAGE pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAGE
Annual income on $10K today (after 15% tax)
$1,958.53/yr
After 10yr DRIP, annual income (after tax)
$7,828.74/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,030,287.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAGE + PLD for your $10,000?

SAGE: 50%PLD: 50%
100% PLD50/50100% SAGE
Portfolio after 10yr
$3.00M
Annual income
$2,379,967.73/yr
Blended yield
79.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SAGE
Analyst Ratings
7
Buy
27
Hold
2
Sell
Consensus: Hold
Price Target
$37.33
+330.1% upside vs current
Range: $5.00 — $105.00
Altman Z
-5.3
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAGE buys
0
PLD buys
0
No recent congressional trades found for SAGE or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAGEPLD
Forward yield23.04%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$87.8K$5.91M
Annual income after 10y$9,210.28$4,750,725.19
Total dividends collected$53.6K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$37.33$136.00

Year-by-year: SAGE vs PLD ($10,000, DRIP)

YearSAGE PortfolioSAGE Income/yrPLD PortfolioPLD Income/yrGap
1$13,004$2,304.15$11,241$540.96+$1.8KSAGE
2$16,715$2,800.32$13,019$991.13+$3.7KSAGE
3$21,249$3,363.90$15,801$1,870.97+$5.4KSAGE
4$26,733$3,996.60$20,609$3,701.21+$6.1KSAGE
5$33,303$4,699.14$29,919$7,867.97+$3.4KSAGE
6← crossover$41,105$5,471.12$50,631$18,617.74$9.5KPLD
7$50,294$6,311.13$105,528$51,352.20$55.2KPLD
8$61,031$7,216.72$287,364$174,449.42$226.3KPLD
9$73,488$8,184.51$1,081,760$774,280.77$1.01MPLD
10$87,842$9,210.28$5,908,209$4,750,725.19$5.82MPLD

SAGE vs PLD: Complete Analysis 2026

SAGEStock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Full SAGE Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SAGE vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAGE vs SCHDSAGE vs JEPISAGE vs OSAGE vs KOSAGE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.